Annual report pursuant to Section 13 and 15(d)

Related Party Agreements (Narrative) (Details)

v3.22.1
Related Party Agreements (Narrative) (Details)
 12 Months Ended
Jun. 11, 2020
USD ($)
Jan. 01, 2017
USD ($)
shares
Jul. 26, 2016
USD ($)
shares
Jul. 22, 2016
Mar. 13, 2015
Dec. 31, 2021
USD ($)
item
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
shares
Dec. 31, 2016
shares
Related Party Transaction [Line Items]                  
Common stock, shares issuable | shares           2,536,607 2,103,122    
Proceeds from issuance of common shares           $ 0 $ 37,230,000    
Preferred stock voting rights multiplier     1.1            
Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares           68,870 83,055    
At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares           $ 71,900,000 $ 59,800,000    
Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares $ 37,200,000                
Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Shares issuable on conversion, per share converted | shares     1            
Fortress Biotech, Inc [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from related party debt     $ 2,000,000.0            
Percentage of fully diluted equity           2.50% 2.50%    
Expenses from related party transaction           $ 500,000 $ 500,000    
Founders agreement term     15 years            
Agreement renewal term     1 year            
Stock dividend (as a percent)     2.50%            
Paid in kind dividend, period prior to payment date for measuring ownership     1 day            
Equity fee, period for payment after financing           5 days      
Equity fee payable in shares (as a percent)           (2.50%)      
Cash fee (as a percent)           (4.50%)      
Cash fee, period for payment           90 days      
Change in control fee, multiplier | item           5      
Change in control fee, measurement period           12 months      
Change in control fee, specified rate component           4.50%      
MSA agreement term         5 years        
Annual consulting fee           $ 500,000      
Consulting fee when net assets exceed threshold           1,000,000.0      
Net assets threshold           $ 100,000,000      
Preferred Stock, Dividend Rate, Percentage     2.50%            
Fortress Biotech, Inc [Member] | At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Shares issued for services (in shares) | shares           576,157 342,773 286,390  
Common stock, shares issuable | shares           51,295 101,632    
Proceeds from issuance of common shares           $ 71,900,000 $ 59,800,000    
Common shares issuable recorded - Founders Agreement | shares           51,295 101,632    
Percentage of fully diluted equity           2.50% 2.50% 2.50%  
Fortress Biotech, Inc [Member] | Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Shares issued for services (in shares) | shares             286,390    
Proceeds from issuance of common shares             $ 37,200,000    
Percentage of fully diluted equity             2.50%    
Fortress Biotech, Inc [Member] | General and administrative [Member] | At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction           $ 1,900,000 $ 1,500,000    
Fortress Biotech, Inc [Member] | General and administrative [Member] | Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction             900,000    
Fortress Biotech, Inc [Member] | Class B Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Common stock, shares issuable | shares                 7,000,000
Fortress Biotech, Inc [Member] | Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued in conversion | shares     7,000,000.0            
Fortress Biotech, Inc [Member] | Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Percentage of fully diluted equity       2.50%          
Number of shares issued in conversion | shares     250,000            
Director [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction           106,000 113,000    
Annual consulting fee           50,000      
Value of shares granted as compensation           $ 56,000 $ 63,000    
Director [Member] | Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares           13,774 16,611    
Director [Member] | Maximum                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation           $ 50,000      
Number of shares granted as compensation | shares           10,000      
Board of Directors Chairman [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction           $ 116,000 $ 122,000    
Annual consulting fee   $ 60,000              
Value of shares granted as compensation           $ 56,000 $ 62,000    
Board of Directors Chairman [Member] | Restricted Stock Awards [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued | shares           13,774 16,611    
Board of Directors Chairman [Member] | Maximum                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation   $ 50,000              
Number of shares granted as compensation | shares   10,000